Symposium hosted by Eric S. Winer, MD, and Grzegorz S. Nowakowski, MDUpdated data for 10 evaluable patients in Curis's PCNSL studyExperts will present at the virtual meeting, free and open to the public, on September 26, 2024LEXINGTON, Mass., Sept. 23, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced the 3rd Annual Symposium on IRAK4 in Cancer taking place virtual ...